stockportfolio.pro
Stocks / HCM vs MESO
HCM vs MESO
HUTCHMED (China) Limited and Mesoblast Limited side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| HUTCHMED (China) Limited (HCM) | Mesoblast Limited (MESO) | |
|---|---|---|
| Market cap | $1.8B | $1.8B |
| Revenue (latest FY) | $548.51M | $17.20M |
| Net income (latest FY) | $456.91M | $-102.14M |
| Revenue growth (5y CAGR) | 8.8% | 19.0% |
| Net margin | 83.3% | -593.9% |
| Return on equity | 36.9% | -17.1% |
| P/E ratio | 4.0 | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 3 | 0 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open HCM — free Open MESO — freeFrequently asked questions
Which is bigger, HCM or MESO?
HUTCHMED (China) Limited is larger by market capitalization — $1.8B versus $1.8B.
Which grows faster, HCM or MESO?
Over the last five fiscal years, Mesoblast Limited grew revenue faster — 19.0%/yr versus 8.8%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.